Early studies show that exogenous IL-2 supplementation prevents disease progression and contributes to inducing immunosuppression in mice with established autoimmune diseases, including Type I diabetes, EA, experimental myasthenia, and lupus (131–138). Here, IL2 is linked to autoimmune disease.